Abbott (NYSE: ABT) announced results from an analysis of three-year long-term data from an ongoing open-label extension of the HUMIRA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE